BTAI

BioXcel Therapeutics, Inc.

OTC· Pharmaceutical Preparations· Inc. DE· CIK 0001720893 Biotech & Drug Discovery

—

Market cap

$2.3M

Nano cap

Median target

$12.00

range $5.00–38.00

Since first trade

+11.5%

from $0.0429 · Sep 8

30 days

+35.6%

from $0.0353

Range since listing

$0.0353–0.0615

−22% from high · low Sep 24

Avg volume 16D

819.2K

Sep 8 spike 6.29M

Short interest

6.12M

≈19.6% of shares · +84.8%

Days to cover

1.0

at average volume

Insider net

-$43.1K

0 buyers · 4 sellers · 12 mo

Filing reports

analyzed by SecBot

SecBot read BEARISH 5 reports · 90 days

Balance 5 bearish · 0 bullish oldest → newest, height = score

Avg score

·High conf. 5/5 ·Next Earnings date, Nov 10, 2026

Strongest BEARISH BioXcel Therapeutics filed for Chapter 11 bankruptcy on August 27, 2026, and this 8-K reports two terminal…

All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

InsidersBEARISH

4 insiders sold $43.1K.
Short sellersBUILDING

Short interest +84.8% to 6.12M shares. 1.0 days to cover, ≈19.6% of shares.
SocialQUIET

No Reddit mentions this week. Last mention Oct 12.

The Street

last action Apr 2026

Recent actions

Date	Firm	Action	Rating
Apr 2, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
Mar 17, 2026	Rodman & Renshaw INITIATE	INITIATE	Buy
Mar 5, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
Sep 15, 2025	HC Wainwright & Co. REITERATE	REITERATE	Buy
Sep 12, 2025	Mizuho MAINTAIN	MAINTAIN	Neutral
Aug 28, 2025	HC Wainwright & Co. REITERATE	REITERATE	Buy

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 10, 2026

Earnings date

🔒 Fresh data — subscribers only

Nov 14, 2026

FDA decision date

🔒 Fresh data — subscribers only

Recent

Oct 5, 2026

Clinical Trial

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

Phase Phase 2 — COMPLETED

Oct 1, 2026

Clinical Trial

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Phase Phase 3 — TERMINATED

Sep 8, 2026

Listing

Delisted: BTAI — removed from the Nasdaq symbol directory

BioXcel Therapeutics, Inc. - Common Stock

Aug 31, 2026

Short interest

Short Interest: BTAI up 85% to 6.1M shares

Settlement 2026-08-31 | Days to cover: 1.00 | ≈19.56% of shares outstanding (est.)

Aug 28, 2026

Contract

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders

Insider ledger

Form 4

bought · 0 insiders

$43.1K

sold · 4 insiders

Date	Insider	Type	Value
Aug 12, 2026	Atkins Susan E. Director	AWARD	17,000 sh
Jun 15, 2026	Yocca Frank Chief Scientific Officer	EXERCISE	35 sh
Jun 15, 2026	Mehta Vimal CEO and President	EXERCISE	219 sh
Jun 15, 2026	Steinhart Richard I Chief Financial Officer	EXERCISE	35 sh
Jun 15, 2026	Rodriguez Javier See Remarks	EXERCISE	35 sh
May 20, 2026	Mehta Vimal CEO and President	SELL	$21.1K
May 20, 2026	Steinhart Richard I Chief Financial Officer	SELL	$7.4K
May 20, 2026	Rodriguez Javier See Remarks	SELL	$7.1K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data — subscribers only
Next Q	🔒 Fresh data — subscribers only
Current FY	🔒 Fresh data — subscribers only
Next FY	🔒 Fresh data — subscribers only